The BREAKWATER trial further evaluated the combination of encorafenib (a BRAF inhibitor) and cetuximab (an anti-EGFR antibody) with or without chemotherapy in patients with BRAF V600E-mutant metastatic CRC. This evidence concerns the gene BRAF and colorectal carcinoma.